Literature DB >> 17440440

A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis.

Li Zhong1, Weihong Zhao, Jianqing Wu, Baozheng Li, Sergei Zolotukhin, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Arun Srivastava.   

Abstract

A 52 kd cellular protein, FK506-binding protein (FKBP52), phosphorylated at tyrosine residues by epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK), inhibits adeno-associated virus 2 (AAV2) second-strand DNA synthesis and transgene expression. FKBP52 is dephosphorylated at tyrosine residues by T-cell protein tyrosine phosphatase (TC-PTP), and TC-PTP over-expression leads to improved viral second-strand DNA synthesis and improved transgene expression. In these studies, we observed that perturbation of EGFR-PTK signaling by a specific inhibitor, Tyrphostin 23 (Tyr23), augmented the transduction efficiency of the single-stranded AAV (ssAAV) vector as well as the self-complementary AAV (scAAV) vector. Similarly, tyrosine-dephosphorylation of FKBP52 by TC-PTP resulted in increased transduction by both vectors. These data suggested that EGFR-PTK signaling also affects aspects of AAV transduction other than viral second-strand DNA synthesis. We document that inhibition of EGFR-PTK signaling leads to decreased ubiquitination of AAV2 capsids which, in turn, facilitates nuclear transport by limiting proteasome-mediated degradation of AAV vectors. We also document that Tyr23-mediated increase in AAV2 transduction efficiency is not further enhanced by a specific proteasome inhibitor, MG132. Thus, EGFR-PTK signaling modulates ubiquitin (Ub)/proteasome pathway-mediated intracellular trafficking as well as FKBP52-mediated second-strand DNA synthesis of AAV2 vectors. This has implications in the optimal use of AAV vectors in gene therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440440     DOI: 10.1038/sj.mt.6300170

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  78 in total

Review 1.  Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges.

Authors:  Deepak Raj; Andrew M Davidoff; Amit C Nathwani
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

2.  Viral gene transfer to developing mouse salivary glands.

Authors:  J C Hsu; G Di Pasquale; J S Harunaga; T Onodera; M P Hoffman; J A Chiorini; K M Yamada
Journal:  J Dent Res       Date:  2011-11-17       Impact factor: 6.116

3.  Enhanced long-term transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2.

Authors:  M Ariel Kauss; Laura J Smith; Li Zhong; Arun Srivastava; K K Wong; Saswati Chatterjee
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

4.  High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy.

Authors:  Mengxin Li; Giridhara R Jayandharan; Baozheng Li; Chen Ling; Wenqin Ma; Arun Srivastava; Li Zhong
Journal:  Hum Gene Ther       Date:  2010-10-06       Impact factor: 5.695

5.  Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells.

Authors:  R Sayroo; D Nolasco; Z Yin; Y Colon-Cortes; M Pandya; C Ling; G Aslanidi
Journal:  Gene Ther       Date:  2015-10-08       Impact factor: 5.250

6.  Adeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector.

Authors:  Arun Srivastava
Journal:  Hum Gene Ther       Date:  2016-01       Impact factor: 5.695

7.  Mechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors.

Authors:  Angela M Mitchell; R Jude Samulski
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

8.  Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates.

Authors:  Knut Stieger; Josef Schroeder; Nathalie Provost; Alexandra Mendes-Madeira; Brahim Belbellaa; Guylène Le Meur; Michel Weber; Jack-Yves Deschamps; Birgit Lorenz; Philippe Moullier; Fabienne Rolling
Journal:  Mol Ther       Date:  2008-12-23       Impact factor: 11.454

9.  AAV-mediated lysophosphatidylcholine acyltransferase 1 (Lpcat1) gene replacement therapy rescues retinal degeneration in rd11 mice.

Authors:  Xufeng Dai; Juanjuan Han; Yan Qi; Hua Zhang; Lue Xiang; Jineng Lv; Jie Li; Wen-Tao Deng; Bo Chang; William W Hauswirth; Ji-jing Pang
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-20       Impact factor: 4.799

Review 10.  Gene therapy using adeno-associated virus vectors.

Authors:  Shyam Daya; Kenneth I Berns
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.